If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||
![]() American Journal of TransplantationVolume 6 Issue 3, Pages 557 - 564 Published Online: 17 Jan 2006 © 2010 American Society of Transplantation and the American Society of Transplant Surgeons
Abstract | References | Full Text: HTML, PDF (Size: 313K) | Related Articles | Citation Tracking Elective Liver Transplantation for the Treatment of Classical Maple Syrup Urine Disease Copyright 2006 The Authors Journal compilation © 2006 The American Society of Transplantation and the American Society of Transplant Surgeons KEYWORDS Branched-chain ketoacid dehydrogenase • liver transplantation • maple syrup urine disease • metabolic disease • pediatric ABSTRACTAn 8.5-year-old girl with classical maple syrup urine disease (MSUD) required liver transplantation for hypervitaminosis A and was effectively cured of MSUD over an 8-year clinical follow-up period. We developed a collaborative multidisciplinary effort to evaluate the effects of elective liver transplantation in 10 additional children (age range 1.9–20.5 years) with classical MSUD. Patients were transplanted with whole cadaveric livers under a protocol designed to optimize safe pre- and post-transplant management of MSUD. All patients are alive and well with normal allograft function after 106 months of follow-up in the index patient and a median follow-up period of 14 months (range 4–18 months) in the 10 remaining patients. Leucine, isoleucine and valine levels stabilized within 6 hours post-transplant and remained so on an unrestricted protein intake in all patients. Metabolic cure was documented as a sustained increase in weight-adjusted leucine tolerance, normalization of plasma concentration relationships among branched-chain and other essential and nonessential amino acids, and metabolic and clinical stability during protein loading and intercurrent illnesses. Costs and risks associated with surgery and immune suppression were similar to other pediatric liver transplant populations. Received 9 September 2005, revised 21 October 2005 and accepted for publication 14 November 2005 |